IRWD (Ironwood Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

IRWD (Ironwood Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

Mkt Cap$629M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Revenue (TTM)$296M

Net Income (TTM)$24M

EPS (TTM)$0.13

Free Cash Flow (TTM)$127M

Gross Margin90.6%

Op. Margin40.1%

Net Margin8.1%

FCF Margin42.9%

P/S Ratio (TTM)2.1x

P/E Ratio (TTM)26.2x

YoY Rev Growth-15.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$104M	$104M	$60M
Q2 23	$107M	$88M	-$1.1B
Q3 23	$114M	$113M	$49M
Q4 23	$118M	$118M	$38M
Q1 24	$75M	$49M	$11M
Q2 24	$94M	$94M	$25M
Q3 24	$92M	$62M	$26M
Q4 24	$91M	$91M	$31M
Q1 25	$41M	$14M	-$29M
Q2 25	$85M	$85M	$45M
Q3 25	$122M	$122M	$75M
Q4 25	$48M	$47M	$27M

Valuation

Quarter	P/S	P/E
Q1 23	1.5x	3.5x
Q2 23	1.5x	—
Q3 23	1.5x	—
Q4 23	1.4x	—
Q1 24	1.5x	—
Q2 24	1.6x	68.2x
Q3 24	1.7x	—
Q4 24	1.8x	714.2x
Q1 25	2.0x	—
Q2 25	2.0x	—
Q3 25	1.9x	22.0x
Q4 25	2.1x	26.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$80M	$80M
Q2 23	$35M	$35M
Q3 23	$32M	$32M
Q4 23	$36M	$36M
Q1 24	$45M	$45M
Q2 24	$33M	$33M
Q3 24	$10M	$10M
Q4 24	$15M	$15M
Q1 25	$20M	$20M
Q2 25	-$15M	-$15M
Q3 25	$48M	$48M
Q4 25	$75M	$75M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$13K
Q2 23	$0
Q3 23	$49K
Q4 23	$211K
Q1 24	$68K
Q2 24	$58K
Q3 24	$16K
Q4 24	$0
Q1 25	$31K
Q2 25	$2K
Q3 25	$2K
Q4 25	$1K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+6.7%	+10.8%
Q2 23	+10.4%	+2763.5%
Q3 23	+4.7%	+62.2%
Q4 23	+9.7%	+105.9%
Q1 24	-28.0%	+45.2%
Q2 24	-12.1%	-94.2%
Q3 24	-19.5%	+1.3%
Q4 24	-23.0%	-26.1%
Q1 25	-45.1%	+10.0%
Q2 25	-9.7%	-42.5%
Q3 25	+33.3%	-29.4%
Q4 25	-47.3%	-65.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$7M	6.9%
Q2 23	$36M	33.4%
Q3 23	$8M	7.0%
Q4 23	$9M	7.4%
Q1 24	$8M	11.2%
Q2 24	$9M	9.1%
Q3 24	$8M	9.1%
Q4 24	$0	0.0%
Q1 25	$5M	12.9%
Q2 25	$5M	5.3%
Q3 25	$4M	3.0%
Q4 25	$12M	25.1%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$13M	$31M
Q2 23	$1.1B	$32M
Q3 23	$32M	$32M
Q4 23	$36M	$39M
Q1 24	$26M	—
Q2 24	$30M	$37M
Q3 24	$30M	$36M
Q4 24	$25M	$34M
Q1 25	$27M	—
Q2 25	$23M	$17M
Q3 25	$22M	$22M
Q4 25	$22M	$19M

Revenue Segments

Quarter	Collaborative arrangement, collaboration and license agreements	Collaborative arrangement, other agreements	Collaborative arrangements revenue
Q1 23	$91K	$580K	$104M
Q2 23	$121K	—	$107M

Revenue by Geography

Quarter	Europe and Other	North America
Q3 23	$714K	$111M
Q1 24	$706K	$72M
Q2 24	$833K	$92M
Q3 24	$807K	$89M
Q1 25	$811K	$39M
Q2 25	$904K	$86M
Q3 25	$944K	$120M
Q4 25	$974K	$46M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$742M	$0	$742M
Q2 23	$175M	$0	$175M
Q3 23	$110M	$0	$110M
Q4 23	$92M	$0	$92M
Q1 24	$122M	$0	$122M
Q2 24	$106M	$0	$106M
Q3 24	$88M	$0	$88M
Q4 24	$89M	$0	$89M
Q1 25	$108M	$0	$108M
Q2 25	$93M	$0	$93M
Q3 25	$140M	$0	$140M
Q4 25	$215M	$0	$215M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	187M	+0.8%
Q2 23	155M	-16.8%
Q3 23	187M	+20.3%
Q4 23	156M	-16.5%
Q1 24	158M	+1.1%
Q2 24	159M	+0.8%
Q3 24	160M	+0.8%
Q4 24	160M	+0.1%
Q1 25	161M	+0.3%
Q2 25	162M	+0.5%
Q3 25	178M	+9.9%
Q4 25	178M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$165K	464
FY 15	$316K	474
FY 16	$406K	674
FY 17	$409K	730
FY 18	$673K	515
FY 19	$1M	317
FY 20	$2M	232
FY 21	$2M	219
FY 22	$2M	219
FY 23	$2M	267
FY 24	$1M	253
FY 25	$1K	200K